Lupin biosimilars are becoming an important part of Lupin Limited’s global growth strategy. The company is expanding its portfolio across biosimilars, complex generics, 505(b)(2) products and specialty medicines while increasing its focus on innovation in India. Lupin’s FY26 integrated report says it expects to bring 50+ products to the U.S. over the next three years, including biosimilars and 505(b)(2) products.
Quick Summary
Lupin is building multiple growth engines through biosimilars, complex generics, 505(b)(2) products and specialty medicines. Its biosimilar portfolio includes Pegfilgrastim and Ranibizumab, while Aflibercept and Etanercept remain part of its broader pipeline. Lupin also plans to strengthen innovation in India through in-house R&D, licensing and differentiated products.
Lupin Biosimilars: Key Highlights
| Key Area | Lupin’s Strategy |
|---|---|
| Biosimilars | Pegfilgrastim, Ranibizumab and other pipeline products |
| U.S. portfolio | 50+ products planned over the next 3 years |
| 505(b)(2) | New differentiated products for the U.S. |
| India innovation | Greater focus on proprietary and innovative medicines |
| R&D | Focus on complex products, biosimilars and specialty therapies |
| Global markets | U.S., Europe, India and other international markets |
Lupin’s FY26 report identifies biosimilars as a significant growth opportunity, particularly in the U.S., alongside respiratory products, complex injectables and specialty therapies.
Lupin Biosimilar Pipeline
Lupin has been expanding its biosimilar research and commercialization capabilities across major global markets.
Its biosimilar portfolio covers therapeutic areas such as:
- Oncology and supportive care
- Ophthalmology
- Immunology and inflammatory diseases
- Respiratory diseases
Lupin says its biosimilar development capabilities extend across the U.S., Europe, Japan, India and emerging markets.
Key Lupin Biosimilars
| Biosimilar | Status / Update |
|---|---|
| Pegfilgrastim | Lupin received U.S. FDA approval for Armlupeg in December 2025 |
| Ranibizumab | U.S. FDA approved Ranluspec in June 2026 |
| Aflibercept | Part of Lupin’s biosimilar development pipeline |
| Etanercept | Part of the broader biosimilar pipeline |
| Denosumab | Lupin reported progress in development and regulatory filings |
Lupin’s FY26 integrated report states that it achieved U.S. FDA approval for Pegfilgrastim and received European approval for Ranibizumab, while also advancing programs for Aflibercept and other biosimilars.
Lupin’s First U.S. Biosimilar: Pegfilgrastim
A major milestone for Lupin biosimilars came in December 2025 when the U.S. FDA approved Armlupeg, Lupin’s biosimilar to Neulasta (pegfilgrastim).
Pegfilgrastim is a long-acting therapy used to reduce the risk of infection associated with chemotherapy-induced neutropenia.
The approval established an important foundation for Lupin’s expansion into the U.S. biologics market.
Ranibizumab Biosimilar Gets U.S. FDA Approval
Lupin further strengthened its biosimilar portfolio in June 2026 when the U.S. FDA approved Ranluspec (ranibizumab-hkdz).
According to Lupin, Ranluspec was approved as an interchangeable biosimilar to Lucentis and is available in both vials and pre-filled syringes.
The product is used for several ophthalmic conditions involving abnormal blood-vessel growth and retinal complications.
Lupin had also received European Commission approval for its Ranibizumab biosimilar earlier in 2026.
Can Lupin Biosimilars Cross $100 Million?
Lupin management has previously discussed the potential for its near-term biosimilar basket to generate approximately $100 million or more over a two-to-three-year period, depending on approvals, launches and market uptake. The company’s earnings-call discussion specifically highlighted Pegfilgrastim, Ranibizumab and Aflibercept as important near-term opportunities.
This should be viewed as a management opportunity/expectation rather than guaranteed revenue.
The potential growth drivers include:
- Pegfilgrastim
- Ranibizumab
- Aflibercept
- Additional biosimilar programs
- Expansion across the U.S. and European markets
Lupin’s 505(b)(2) Strategy
Biosimilars are not the only differentiated platform in Lupin’s U.S. strategy.
The company is also developing 505(b)(2) products, a regulatory pathway that can be used for certain products that rely partly on previously established information while incorporating changes or improvements.
Lupin’s management has said its first 505(b)(2) products are expected to become contributors from FY27 onward.
Key 505(b)(2) Opportunities
- Dalbavancin
- Apixaban
- Injectable products
- Other differentiated formulations
Management has indicated that Dalbavancin is expected as a FY27 opportunity, while Apixaban has been identified in the broader pipeline.
Lupin Plans 50+ U.S. Product Launches
Lupin is also preparing a broad U.S. launch pipeline.
According to its FY26 integrated report, the company expects to bring 50+ products to the U.S. market over the next three years. The pipeline includes:
- Biosimilars
- Complex generics
- 505(b)(2) products
- Complex injectables
- Exclusive first-to-file opportunities
This strategy is designed to diversify Lupin’s U.S. business and reduce dependence on individual high-value products.
Lupin’s Innovation Strategy in India
India remains another major focus for Lupin.
The company is looking to move beyond a conventional generics-led model by increasing the contribution of innovative, proprietary and differentiated products.
Lupin’s strategy combines:
- In-house R&D
- Strategic licensing
- Novel and differentiated medicines
- Specialty therapies
- Complex products
The company has also stated that it plans to strengthen its innovation ecosystem in India through internal development and licensing of late-stage assets.
Lupin’s India Product Pipeline
Lupin has previously outlined plans to introduce 80+ products in India over a multi-year period, with new launches expected to support domestic growth.
The company’s areas of interest include:
- Cardiology
- Diabetes
- Gastroenterology
- Respiratory
- Oncology
- CNS
- Metabolic disorders
A notable example of the licensing strategy is Lupin’s March 2026 agreement with Zydus Lifesciences to co-market innovative semaglutide injection products in India.
Lupin’s R&D and Biosimilar Capabilities
Research and development remains central to Lupin’s long-term strategy.
According to Lupin’s FY26 integrated report, the company invested ₹2,063.1 crore in R&D during FY26, representing 7.5% of total sales.
The company is focusing R&D resources on:
- Complex generics
- Biosimilars
- Specialty medicines
- Complex injectables
- Long-acting injectables
- Green-propellant products
- 505(b)(2) opportunities
This indicates a gradual shift toward products that require greater scientific, technological and regulatory capabilities.
Lupin Q1 FY27 Performance
Lupin also started FY27 with strong financial performance.
According to reports on the company’s Q1 FY27 results, consolidated revenue from operations increased 33.3% year-on-year to ₹8,217 crore, while net profit increased 16% to ₹1,417 crore. EBITDA increased approximately 42.8% to ₹2,580 crore.
Q1 FY27 Key Numbers
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹8,217 crore |
| YoY revenue growth | 33.3% |
| Net profit | ₹1,417 crore |
| YoY net profit growth | 16% |
| EBITDA | ₹2,580 crore |
| EBITDA margin | 31.4% |
| U.S. sales | About ₹3,435 crore |
| India sales | About ₹2,379 crore |
The U.S. business remained Lupin’s largest geographic contributor, while India also recorded strong growth during the quarter.
Note: Financial figures are period-specific and should be checked against Lupin’s latest official results before making investment decisions. Lupin maintains an official quarterly-results section covering FY2026-27.
Why Are Biosimilars Important for Lupin?
Biosimilars provide Lupin with an opportunity to participate in the growing market for biologic medicines while using its existing strengths in:
- Pharmaceutical R&D
- Manufacturing
- Regulatory expertise
- Global commercialization
- Complex product development
Lupin’s own FY26 report describes biosimilars as an important growth avenue for its U.S. business.
The company’s broader growth model can therefore be summarized as:
Biosimilars + Complex Generics + 505(b)(2) + Specialty Products + Innovation
Lupin’s Future Growth Strategy
Lupin’s future strategy is increasingly based on diversification.
In the U.S.
The company is focusing on:
- Biosimilars
- Complex generics
- Respiratory products
- Complex injectables
- 505(b)(2) products
- Specialty therapies
Lupin’s FY26 report says it wants to double the share of complex products in its U.S. business through respiratory products, complex injectables, 505(b)(2) products and biosimilars.
In India
The company is focusing on:
- Innovative medicines
- New product launches
- Strategic licensing
- In-house R&D
- Chronic therapies
- Specialty opportunities
- Metabolic and other high-need therapeutic areas
Key Lupin Growth Drivers at a Glance
| Growth Driver | Why It Matters |
|---|---|
| Biosimilars | Expands Lupin’s presence in biologics |
| 505(b)(2) | Creates differentiated U.S. products |
| Complex Generics | Supports higher-value product launches |
| Respiratory | Established U.S. strength and pipeline |
| Injectables | High-barrier product opportunity |
| India Innovation | Diversifies the domestic portfolio |
| Licensing | Provides access to external innovation |
| R&D | Builds long-term differentiated pipeline |
What This Means for Lupin’s Future
Lupin is gradually evolving from a primarily traditional generics-focused company toward a more diversified and innovation-led pharmaceutical business.
The most important areas to watch are:
- Execution of biosimilar launches
- U.S. market uptake of Pegfilgrastim and Ranibizumab
- Progress of Aflibercept and other biosimilars
- Commercialization of 505(b)(2) products
- Growth of complex injectables
- New product launches in India
- Licensing and strategic partnerships
- R&D investment and pipeline development
The $100 million biosimilar opportunity is therefore one part of a much broader transformation in Lupin’s portfolio.
Frequently Asked Questions About Lupin Biosimilars
1. What are Lupin biosimilars?
Lupin biosimilars are biologic products developed to be highly similar to already approved reference biologics. Lupin has biosimilar programs across areas including oncology, ophthalmology and immunology.
2. What is Lupin’s first U.S. biosimilar?
Lupin’s first U.S. biosimilar approval was Armlupeg (pegfilgrastim), approved by the U.S. FDA in December 2025.
3. Which Lupin biosimilar received U.S. FDA approval in June 2026?
Ranluspec (ranibizumab-hkdz) received U.S. FDA approval in June 2026 as an interchangeable biosimilar referencing Lucentis.
4. Can Lupin biosimilars generate $100 million?
Lupin management has indicated that its near-term biosimilar basket has the potential to generate approximately $100 million or more over two to three years, depending on approvals, launches and market conditions.
5. What is Lupin’s 505(b)(2) strategy?
Lupin is developing differentiated products through the 505(b)(2) regulatory pathway, with products such as Dalbavancin and Apixaban identified as opportunities in its pipeline.
6. How many products does Lupin plan to launch in the U.S.?
Lupin’s FY26 integrated report states that the company expects to bring 50+ products to the U.S. over the next three years, including biosimilars and 505(b)(2) products.
7. Is Lupin focusing on innovation in India?
Yes. Lupin has stated that it wants to strengthen innovation in India through in-house development and licensing of late-stage assets, alongside its existing product portfolio.
8. What were Lupin’s Q1 FY27 results?
Lupin reported Q1 FY27 revenue from operations of approximately ₹8,217 crore and net profit of ₹1,417 crore, with revenue growing 33.3% year-on-year and net profit rising 16%.
Important Official Links
- Lupin Official Website: Lupin Limited
- Lupin Quarterly Results: Lupin Quarterly Results
- Lupin FY26 Integrated Report: Lupin Integrated Report 2025–26
- Lupin Biosimilars: Lupin Biosimilars Business
Conclusion
Lupin biosimilars are emerging as a key component of the company’s next phase of growth. With Pegfilgrastim already approved in the U.S., Ranibizumab gaining U.S. approval in 2026, and additional programs such as Aflibercept and Etanercept in development, Lupin is building a broader global biologics portfolio.
At the same time, the company is expanding into 505(b)(2) products, complex injectables, specialty medicines and differentiated generics. Its India strategy adds another growth layer through new product launches, licensing and greater investment in innovation.
With 50+ U.S. products planned over the next three years and a biosimilar portfolio that management believes could have a roughly $100 million-plus opportunity over two to three years, Lupin’s strategy is increasingly focused on creating multiple growth engines rather than relying only on conventional generics.
Recommended Products
